Skip to main content
. Author manuscript; available in PMC: 2008 Nov 4.
Published in final edited form as: Neuroscience. 2008 Jan 25;152(3):753–760. doi: 10.1016/j.neuroscience.2008.01.022

Figure 4.

Figure 4

Effects of modulation of CB1 and CB2 receptor activation on neurological function after MCAO. In parallel with the changes in cerebral infarction, administration of a CB1 antagonist (20mg/kg, i.p.) improved motor function, while administrations of a CB2 antagonist tended to worsen motor function (A). Administration of CB2 agonist (1mg/kg, i.v.) alone improved motor function and this protection which was totally reversed by CB2 antagonist (20mg/kg, i.p.); while administration of CB2 agonist with CB1 antagonist together significantly attenuated neurological deficits after MCAO (B). (n=7–8 in each group, data were expressed as Mean±SEM, *p<0.05 vs vehicle treated control group, **p<0.01 vs vehicle treated control group)